---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-218131"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:14:03.211000+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics raises ~$258.8M in public offering of common and Series B preferred stock

## Summary
- 10,666,600 common shares at $18.75/share and 20,000 Series B non-voting convertible preferred shares at $1,250.06250/share offered.
- Underwriters' option for 1,800,000 additional common shares exercised in full on September 12, 2024.
- Aggregate gross proceeds approximately $258.8 million before underwriting discounts and expenses.
- Net proceeds expected to fund operations into the second half of 2027.
- Closing of the offering expected on September 13, 2024 under existing shelf registration statement.

## SEC filing metadata
- accession: 0001193125-24-218131
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312524218131/0001193125-24-218131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312524218131/d881013d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-218131
- JSON: https://secwatch.observer/filing/0001193125-24-218131.json
- Plain text: https://secwatch.observer/filing/0001193125-24-218131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.